Pass-through rebates do not violate non-interference clause but they do increase savings for seniors
By Jim C. Stansel | July 2, 2018
For more than a decade, Medicare Part D has successfully provided seniors with comprehensive prescription drug coverage. Key to its success is a unique, market-based structure of private-sector...
Read More
Guest post: Excellent care for LGBTQ patients requires cultural humility and specific medical knowledge
By Guest Contributor | June 28, 2018
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Medicare Part D cliff ahead
By Juliet Johnson | June 21, 2018
Medicare Part D has been providing seniors with access to prescription drug coverage that meets their needs for more than a decade. Today, more than 42 million people are enrolled in Part D and 90...
Read More
Aspen Spotlight Health: Discussing the forefront of innovation
By Katie Koziara | June 21, 2018
For the second year in a row, PhRMA is proud to participate in Aspen’s Spotlight Health Conference. As the opening session of Aspen Ideas Festival, Spotlight Health welcomes over 1,500 experts and...
Read More
Patients with a deductible have seen their out-of-pocket costs for brand medicines increase 50 percent since 2014
By Holly Campbell | June 20, 2018
Spending on medicines is growing at the slowest rate in years, but according to a new IQVIA Institute for Human Data Science article, at the pharmacy, commercially insured patients with a...
Read More
Celebrating U.S. innovation as USPTO issues the 10 millionth patent
By Nicole Longo | June 19, 2018
The U.S. patent system has supported innovation and discovery dating back to the founding of our nation and the signing of the U.S. Constitution, encouraging Americans to continue to search for...
Read More
Long-awaited FDA guidance addresses one key obstacle to value-based contracting
By Jim C. Stansel | June 19, 2018
As part of the broader shift away from paying for volume to paying for value in health care, payors are increasingly pursuing value-based or results-based contracts with biopharmaceutical...
Read More
ICYMI - Analysis finds higher outpatient drug spending at 340B hospitals
By Nicole Longo | June 18, 2018
Did you know 340B hospitals prescribe more medicines or more expensive medicines? A recent analysis by Milliman, commissioned by PhRMA, found hospitals participating in the 340B drug pricing...
Read More
Part D cliff looms for seniors, as program stability could be in jeopardy
By Juliet Johnson | June 18, 2018
For more than a decade, Medicare Part D has successfully provided seniors comprehensive prescription drug coverage that meets their needs, while its market-based structure has kept overall program...
Read More
Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill
By Andrew Powaleny | June 14, 2018
This week, the new era of medicine was brought to Capitol Hill in Washington, DC when 55 biopharmaceutical researchers from 20 PhRMA member companies held 79 meetings with members of Congress and...
Read More
Medicare Monday (100)
340B Spotlight (36)
Cost & Consequence (0)
